A5103258929- Bone health and treatments
- Prostate Cancer Treatment and Research
- Cancer Diagnosis and Treatment
- Radiopharmaceutical Chemistry and Applications
- Immune cells in cancer
- Cancer Treatment and Pharmacology
- Retinal Diseases and Treatments
- Glaucoma and retinal disorders
- Single-cell and spatial transcriptomics
- Extracellular vesicles in disease
- Tryptophan and brain disorders
- Management of metastatic bone disease
- Atherosclerosis and Cardiovascular Diseases
- Medical Imaging and Pathology Studies
- Ophthalmology and Visual Impairment Studies
- Brain Metastases and Treatment
Nanchang University
2023-2025
Inner Mongolia Comprehensive Disease Prevention and Control Center
2019
Stanford Cancer Institute
2016
Vector Oncology (United States)
2013
Amgen (United States)
2010-2013
Kantonsspital Graubünden
2013
IQVIA (United States)
2013
Penn State Milton S. Hershey Medical Center
2010
Centre Hospitalier Universitaire Brugmann
2010
University of Sussex
2010
Abstract Background: Patients with breast cancer and bone metastases often experience skeletal-related events (SREs) pain, which may impact health-related quality of life (HRQoL). Denosumab is a fully human monoclonal antibody against RANKL shown to be superior in delaying/preventing SREs more effective delaying moderate or severe pain patients advanced compared zoledronic acid (ZA). Previously reported results from this study population showed that both denosumab ZA improvement maintenance...
4533 Background: Bone metastases from castrate-resistant prostate cancer (CRPC) are associated with osteoclast-mediated bone destruction and skeletal-related events (SREs). Denosumab is a fully human monoclonal antibody against RANKL, key mediator of osteoclast formation, function, survival. Previous results phase III trial showed denosumab was superior to zoledronic acid (ZA) in delaying or preventing SREs (pathologic fracture, radiation surgery bone, spinal cord compression) patients CRPC....
Abstract Background: Bone is the most common site of distant metastasis in advanced breast cancer patients (pts). Development bone metastases (mets) associated with substantial morbidity including skeletal complications, decreased quality life, increased pain, and shortened lifespan. Pt burden symptoms mets has been assessed tumor types other than or metastatic disease not specific to bone. This study characterizes patterns pt-reported over time among pts mets. Methods: The Oncology Services...